Esperion Therapeutics (ESPR) Upgraded at Citigroup
Citigroup upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a neutral rating to a buy rating in a report published on Friday morning, MarketBeat.com reports. The brokerage currently has $75.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $57.00.
Several other analysts have also commented on ESPR. Northland Securities increased their price target on shares of Esperion Therapeutics from $100.00 to $121.00 and gave the company a buy rating in a research report on Thursday, April 19th. ValuEngine upgraded shares of Esperion Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Bank of America restated an underperform rating on shares of Esperion Therapeutics in a report on Wednesday, May 2nd. Deutsche Bank cut their price objective on shares of Esperion Therapeutics from $100.00 to $75.00 and set a buy rating on the stock in a report on Thursday, May 3rd. Finally, JPMorgan Chase & Co. downgraded shares of Esperion Therapeutics from a neutral rating to an underweight rating and cut their price objective for the company from $100.54 to $41.00 in a report on Thursday, May 3rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $82.04.
ESPR stock opened at $47.51 on Friday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -7.02 and a beta of 2.29. Esperion Therapeutics has a one year low of $33.06 and a one year high of $82.68.
In other Esperion Therapeutics news, major shareholder Target N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction that occurred on Thursday, July 12th. The shares were bought at an average price of $41.77 per share, for a total transaction of $2,088,500.00. Following the acquisition, the insider now owns 3,232,964 shares in the company, valued at $135,040,906.28. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Target N. V. Biotech purchased 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 5th. The stock was acquired at an average price of $38.47 per share, for a total transaction of $2,308,200.00. Following the acquisition, the insider now owns 3,012,964 shares in the company, valued at approximately $115,908,725.08. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 330,000 shares of company stock worth $13,259,300. 14.50% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Quantbot Technologies LP increased its holdings in Esperion Therapeutics by 348.6% in the 1st quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,234 shares during the period. Bayesian Capital Management LP acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $231,000. Xact Kapitalforvaltning AB acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $250,000. Keybank National Association OH increased its holdings in Esperion Therapeutics by 97.7% in the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 3,787 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its holdings in Esperion Therapeutics by 40.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 2,224 shares during the period. Institutional investors own 97.64% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Recommended Story: What does relative strength index mean?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.